Tim Opler

Graig Suvannavejh × Tim Opler × Yaron Werber × Paul Matteis × Brian Skorney

Biotech is decisively outperforming, with XBI +24% YTD versus +9% for the S&P 500, as Graig sees FDA headwinds turning into tailwinds alongside 14 IPOs and $300B+ of pharma revenue at LOE risk.Reverse mergers now rival traditional IPOs, while J&J’s $785M Sail deal and $2.6B acquisition option reinforce hot in vivo CAR-T M&A.Alnylam’s roughly 30% TTR sell-off and Novo’s ZEUS miss leave upcoming data and year-end M&A as key tests.

Grace Colon × Tim Opler × Graig Suvannavejh × Eric Schmidt

The Trump–Lilly–Novo agreement’s $4,000 annual Mounjaro or Ozempic price for Medicare/Medicaid may establish a “large markets, medium prices” benchmark, supporting Tim Opler’s XBI 150-plus thesis.Against a $90B pharma revenue hole and subdued deal pace, RAPT’s $35M China-licensed asset becoming a $2.2B GSK takeout illustrates pivot economics, while FDA instability, MFN reopening, China, and IPO quality remain key risks.

Eric Schmidt × Brad Loncar × Tim Opler × Tess Cameron

Biotech M&A has reached 18 takeouts worth over $40B in 2025, as patent cliffs drive pharma’s inorganic expansion and Capstan returns to early science.Median bidders remain 1, keeping Blueprint and Verona premiums modest, while Capstan’s $2.1B in vivo CAR-T deal may be either a wider XBI signal or a one-off; MFN rumors and upcoming data remain key watchpoints.

Chris Garabedian × Daphne Zohar × Sam Fazeli × Tess Cameron × Paul Matteis × Tim Opler

XBI remains down YTD, but this year's IPO cohort is up 50–60% and follow-ons work, signaling a fund-specific recovery amid scarce private capital.China biotech rose almost 40% last month on rumored "$500 million plus" deals, while copycat competition discounts exposed US smid-caps; FDA subjectivity remains a tail risk as KalVista's approval is "very likely" despite an inferential CRL report.

Chris Garabedian × Josh Schimmer × Nina Kjellson × Mike Yee × Tim Opler

Summit’s PD-1×VEGF bispecific missed overall survival at p=0.0575, sending shares down 25% despite a PFS hit and 20% lower mortality risk in Western patients.Tim Opler sees VEGF×PD-1 becoming oncology’s backbone, while Pfizer’s 3SBio license and Seagen acquisition give it control for ADC combinations.Macro uncertainty favors discounted commercial-stage M&A, and Gilead’s June 19 lenacapavir PDUFA will test FDA functionality.

Daphne Zohar × Josh Schimmer × Tim Opler × John Maraganore × Paul Matteis

After April 7, XBI rose about 15% and BBC 30%, but remained down 12% and 24% year to date, offering no proof generalists returned.Makary’s FDA agenda could expand rare-disease optionality through smaller decisive datasets and conditional approvals, but staffing disruption and scientific independence remain execution risks.Cobenfy’s failed adjunctive study cut Citi’s peak-sales view to $2.8 billion, while real-world combination use and Alzheimer’s psychosis preserve upside scenarios.

Chris Garabedian × Tim Opler × Bruce Booth × Sam Fazeli

Biotech’s 2025 selloff appears driven more by forced selling and weak marginal demand than deteriorating science, with XBI at $84.45, down 4% for the week.Venture capital remains near $5 billion quarterly while new financings have fallen to barely above 50 and average rounds reached $65 million, concentrating capital in fewer, more disciplined companies.Reported HHS reductions create FDA execution risk as China expands, while Tagrisso’s EGFR-lung-cancer defense keeps physician adoption—not headline efficacy—the key catalyst.

Brad Loncar × Eric Schmidt × Tess Cameron × Luba Greenwood × Tim Opler × Adam Feuerstein

About 200 of roughly 700 public biotechs trade at negative enterprise value, making the sector’s “army of zombies” a capital-allocation and governance problem rather than a diagnosis.Cash-out optionality could test shareholder support for a failed pivot, but management incentives resist returning capital; Taysha shows revival is possible, while CARGO illustrates when the funded experiment simply fails.

Daphne Zohar × Paul Matteis × Brian Skorney × Tim Opler × Abe Ceesay

Biotech sentiment improved after JPM, but the XBI’s 12% lag versus the S&P kept the shift “less negative,” not risk-on.Stronger 2025 pharma M&A capacity, wall-crossed PIPEs, and GH Research’s 15-to-16-point MADRS difference offered catalysts while exposing access and disclosure tensions.Symbravo’s launch, Ingrezza’s Part D pressure, and Eylea biosimilar erosion leave reimbursement, competition, and execution as key variables.

Chris Garabedian × Tim Opler × Sam Fazeli × Brian Skorney × Luba Greenwood

Novo Nordisk’s Amycretin delivered 22% weight loss at 36 weeks among patients reaching 20 mg and remaining on treatment, but undisclosed discontinuations and limited tolerability data make the as-treated result provisional, making those disclosures the key valuation catalyst.Meanwhile, a roughly 5% technical XBI rebound contrasted with Stifel’s “historic high” M&A pipeline and 17 deals above $75 million upfront in 2024, while health-agency freezes threaten timelines.